Characterization of the metastatic phenotype of a panel of established osteosarcoma cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Ling Ren 1 , Arnulfo Mendoza 1 , Jack Zhu 2 , Joseph W. Briggs 1 , Charles Halsey 3 , Ellen S. Hong 1 , Sandra S. Burkett 4 , James J. Morrow 5 , Michael M. Lizardo 1 , Tanasa Osborne 6 , Samuel Q. Li 5 , Hue H. Luu 7 , Paul Meltzer 2 and Chand Khanna 1 1 Molecular Oncology Section - Metastasis Biology Group, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA 2 Genetic Branch, National Cancer Institute, Bethesda, Maryland, USA 3 Molecular Pathology Unit, Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, USA 4 Comparative Molecular Cytogenetics Core Facility, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA 5 School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA 6 National Institute of Environmental Health, Research Triangle Park, North Carolina, USA 7 Department of Orthopedic Surgery & Rehabilitation Medicine, University of Chicago, Medicine & Biological Sciences, Chicago, USA Correspondence to: Chand Khanna, email: // Keywords : osteosarcoma, PHLDA1/TDAG51, tumor metastasis Received : June 08, 2015 Accepted : July 12, 2015 Published : August 13, 2015 Abstract Osteosarcoma (OS) is the most common bone tumor in pediatric patients. Metastasis is a major cause of mortality and morbidity. The rarity of this disease coupled with the challenges of drug development for metastatic cancers have slowed the delivery of improvements in long-term outcomes for these patients. In this study, we collected 18 OS cell lines, confirmed their expression of bone markers and complex karyotypes, and characterized their in vivo tumorgenicity and metastatic potential. Since prior reports included conflicting descriptions of the metastatic and in vivo phenotypes of these models, there was a need for a comparative assessment of metastatic phenotypes using identical procedures in the hands of a single investigative group. We expect that this single characterization will accelerate the study of this metastatic cancer. Using these models we evaluated the expression of six previously reported metastasis-related OS genes. Ezrin was the only gene consistently differentially expressed in all the pairs of high/low metatstatic OS cells. We then used a subtractive gene expression approach of the high and low human metastatic cells to identify novel genes that may be involved in OS metastasis. PHLDA1 (pleckstrin homology-like domain, family A) was identified as one of the genes more highly expressed in the high metastatic compared to low metastatic cells. Knocking down PHLDA1 with siRNA or shRNA resulted in down regulation of the activities of MAPKs (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 mitogen-activated protein kinases (MAPKs). Reducing the expression of PHLDA1 also delayed OS metastasis progression in mouse xenograft models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“Limited improvement in outcomes and survival of OS patients has been seen since the introduction of chemotherapy in the 1970’s [8-10].”
BackgroundAn Abundance of Ubiquitously Expressed Genes Revealed by Tissue Transcriptome Sequence Data
Ramsköld, D., Wang, E. T., Burge, C. B., & Sandberg, R. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000598 · Cited by 820
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705
Self-citationCanine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291
Self-citationKhanna, C., Prehn, J., Yeung, C., Caylor, J., Tsokos, M., & Helman, L. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1006767007547 · Cited by 207 · cited 5×
“After trypsinization, cells were counted and dilutions of 2x106 viable cells in 100 μl HBSS were injected orthotopically to the para-osseous proximal tibia as previously described [18].”
BackgroundMethodInfluentialSelf-citationA nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies
Jia, S.-F., Worth, L. L., & Kleinerman, E. S. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006623001465 · Cited by 146 · cited 2×
“LM7 Human 100% 91 100% 123 100% 65 [54]”
Modeling metastasis biology and therapy in real time in the mouse lung
Mendoza, A., Hong, S.-H., Osborne, T., Khan, M. A., Campbell, K., Briggs, J., Eleswarapu, A., Buquo, L., Ren, L., Hewitt, S. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40252 · Cited by 92 · cited 1×
“Gene expression profiles of cell lines grown in vitro were compared to expression profiles of the same cell lines at early time points during metastatic colonization using the ex vivo pulmonary metastasis assay (PuMA) [46].”
MethodSelf-citation
Cited by
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161
“The metastatic properties of these clonally related parental and metastatic cell lines have been thoroughly characterized in multiple murine models of metastasis 21 .”
BackgroundMethodInfluentialSelf-citationRoberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Self-citationTegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Nomura, M., Rainusso, N., Lee, Y.-C., Dawson, B., Coarfa, C., Han, R., Larson, J. L., Shuck, R., Kurenbekova, L., & Yustein, J. T. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz026 · Cited by 99
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Self-citation
Metadata
- Authors
- Ren, L., Mendoza, A., Zhu, J., Briggs, J. W., Halsey, C., Hong, E. S., Burkett, S. S., Morrow, J. J., Lizardo, M. M., Osborne, T., Li, S. Q., Luu, H. H., Meltzer, P., & Khanna, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-08-13
- Volume
- 6
- Issue
- 30
- Pages
- 29469-29481
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1908149944
- Cited by
- 119
- References
- 8
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.